Thymogen
Also known as: Glu-Trp, Glutamyl-tryptophan
Overview
Thymogen is a synthetic dipeptide (Glu-Trp) bioregulator derived from the thymus and representing another member of the Khavinson peptide family. It combines glutamic acid and tryptophan to provide immunomodulatory effects primarily targeting T-lymphocyte function. Research suggests it modulates T-cell differentiation, balances cytokine profiles, and may have applications in immune deficiency states associated with aging, chronic illness, or post-chemotherapy recovery.
Mechanism of Action
Thymogen (Glu-Trp) acts as a chromatin-modulating dipeptide similar to Vilon, interacting with DNA-associated proteins to regulate gene expression in immune cells. It influences T-helper cell polarization and cytokine production, potentially through NF-κB pathway modulation similar to other Khavinson peptides. The tryptophan component may additionally influence serotonin and kynurenine pathways that modulate immune tolerance and inflammation.
Potential Benefits
- T-lymphocyte function modulation
- Cytokine balance improvement in immunodeficiency
- Potential recovery support post-chemotherapy
- Anti-inflammatory effects via NF-κB pathway modulation
- Thymus function support in aging
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 100 mcg daily for 5 days |
| Intermediate | 100 mcg daily for 10 days |
| Advanced | 100 mcg daily for 10 days, repeat every 3-6 months |
| Cycle Duration | 5-10 day cycles |
Khavinson dipeptide (Glu-Trp). Thymic immune bioregulator approved in Russia.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High
Standard route.
Intranasal Moderate
Russian-approved intranasal formulation available.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Thymogen:
Immune Support Stack
Layered thymic-immune support for immunocompromised or aging immune systems.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate at 2-8°C after reconstitution. Do not freeze reconstituted solution. |
|---|
Typical vial sizes: 1-5 mg. Add bac water slowly down the side of the vial, swirl gently — do not shake. Use insulin syringe for precise dosing.
Need exact syringe measurements?
Amino Acid Sequence
Glu-Trp
Side Effects & Safety
- Generally well-tolerated
- Minimal reported adverse effects
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside Thymogen for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.